Pfizer: Q4 revenue reaches $17.56 billion, exceeding expectations

Glonghui, February 3rd｜Pfizer reported Q4 revenue of $17.56 billion, compared to an estimate of $16.94 billion; Q4 adjusted earnings per share were $0.66. Pfizer still forecasts 2026 revenue between $59.5 billion and $62.5 billion; it projects 2026 adjusted earnings per share between $2.80 and $3.00. The 2026 guidance reflects the anticipated negative impact of most-favored-nation drug pricing and the Trump administration's prescription drug policies.